A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma

被引：0
|
作者：
Campos, S. [1 ]
Penson, R. [2 ]
Berlin, S. [3 ]
Matulonis, U. [3 ]
Horowitz, N. [3 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
    Nimeiri, Halla S.
    Oza, Amit M.
    Morgan, Robert J.
    Friberg, Gregory
    Kasza, Kristen
    Faoro, Leonardo
    Salgia, Ravi
    Stadler, Walter M.
    Vokes, Everett E.
    Fleming, Gini F.
    GYNECOLOGIC ONCOLOGY, 2008, 110 (01) : 49 - 55
  • [42] Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers
    Escobar, PF
    Markman, M
    Rose, P
    Zanotti, K
    Webster, K
    Belinson, J
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 192 - 196
  • [43] A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Martin, Lainie P.
    Sill, Michael
    Shahin, Mark S.
    Powell, Matthew
    DiSilvestro, Paul
    Landrum, Lisa M.
    Gaillard, Stephanie L.
    Goodheart, Michael J.
    Hoffman, James
    Schilder, Russell J.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 526 - 530
  • [44] A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma
    Smaletz, Oren
    Diz, Maria D. P. E.
    do Carmo, Claudio C.
    Sabbaga, Jorge
    Cunha-Junior, Geraldo F.
    Azevedo, Sergio J.
    Maluf, Fernando C.
    Barrios, Carlos H.
    Costa, Ronaldo L.
    Fontana, Ana G.
    Madrigal, Vivian
    Wainstein, Alberto J.
    Yeda, Fernanda P.
    Alves, Venancio A.
    Moro, Ana M.
    Blasbalg, Roberto
    Scott, Andrew M.
    Hoffman, Eric W.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 272 - 277
  • [45] A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer
    Nakanishi, Toru
    Aoki, Daisuke
    Watanabe, Yoh
    Ando, Yuichi
    Tomotsugu, Naoki
    Sato, Yuji
    Saito, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 422 - 426
  • [46] Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers
    Markman, M
    Webster, K
    Zanotti, K
    Kulp, B
    Peterson, G
    Belinson, J
    GYNECOLOGIC ONCOLOGY, 2004, 95 (01) : 109 - 113
  • [47] Phase I study of intraveneous docetaxel and intraperitoneal oxaliplatin in recurrent ovarian, fallopian tube and peritoneal cancer
    Taylor, Sarah E.
    Li, Ruosha
    Petschauer, Jennifer S.
    Donovan, Heidi
    Zamboni, William C.
    Edwards, Robert P.
    Zorn, Kristen K.
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer
    Hendrickson, Andrea Elisabeth Wahner
    Foster, Nathan R.
    Clasemann, Tracy
    Grudem, Megan
    Klampe, Carolyn
    Block, Matthew Stephen
    Jatoi, Aminah
    Weroha, Saravut John
    Choong, Grace Mei Yee
    Yadav, Siddhartha
    Flickinger, Lynn M.
    Ashley, Gary W.
    Langecker, Peter J.
    Santi, Daniel V.
    Kaufmann, Scott H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer
    Strauss, Hans-Georg
    Hemsen, Alice
    Karbe, Ina
    Lautenschlaeger, Christine
    Persing, Monika
    Thomssen, Christoph
    ANTI-CANCER DRUGS, 2008, 19 (05) : 541 - 545
  • [50] Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Kerliu, Lloreta
    Myruski, Samantha
    Bhatti, Afeefa
    Soni, Priyal
    Petrosius, Paulius
    Pervanas, Helen C.
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 1010 - 1015
12345